Celiac disease is a chronic autoimmune disorder in which the body’s immune system mistakenly attacks the small intestine. It is triggered by the consumption of gluten, a protein found in wheat, barley and rye. The immune reaction damages the tiny finger-like projections (villi) lining the small intestine. As a result, it reduces the body’s ability to absorb nutrients from food. [Read more…]
IPS HEART’s iPSC-Derived Cell Therapy, ISX9-CPC, Secures 8th FDA Regulatory Milestone
IPS HEART Secures 8th FDA Regulatory Milestone with Rare Pediatric Drug Designation for Cardiomyopathy Associated with Muscular Dystrophies
HOUSTON–IPS HEART, Inc., a biopharmaceutical company pioneering induced pluripotent stem cell (iPSC)-derived cell replacement therapies, announced that the FDA has granted Rare Pediatric Drug Designation for ISX9-CPC, for the treatment of cardiomyopathies associated with dystrophinopathies. [Read more…]
Cell Therapy CDMO Cellipont Bioservices Celebrates Major Manufacturing Milestone: Releases 100th GMP Batch
Cell therapy CDMO reaches major manufacturing milestone approximately one year after initiating GMP operations at its Texas facility
THE WOODLANDS, Texas, July 28, 2026 — Cellipont Bioservices, a cell therapy contract development and manufacturing organization, announced the successful release of its 100th GMP batch at its manufacturing facility in The Woodlands, Texas.
The achievement is especially significant given that Cellipont initiated GMP manufacturing operations at the facility in June 2025. Reaching 100 GMP batch releases in approximately one year reflects the strength of the company’s operational infrastructure, the growing demand from its clients, and the dedication of its cross-functional teams. [Read more…]
Aspen Neuroscience Receives FDA RMAT for Sasineprocel (ANPD001), an Autologous iPSC-Based Therapy for PD
SAN DIEGO, July 30, 2026 — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, announced that sasineprocel (ANPD001), its lead investigational product, for the treatment of Parkinson’s Disease (PD) was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA). [Read more…]
Data-Driven Healthcare Starts With Better Patient Insights
Modern medicine generates massive amounts of digital information every single day. Hospitals routinely track everything from heart rates and lab results to medication schedules with extreme precision. These measurements build a comprehensive record of clinical care inside the facility. [Read more…]
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 339
- Next Page »